Search Within

Alexander Edward Drilon

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (53)
  2. Meeting Abstract (45)
  3. Review (5)
  4. Editorial (2)
  5. Research Letter (1)
Groups
  1. Department of Medicine (106)
  2. Sloan Kettering Institute Postdocs (106)
  3. Solid Tumor Oncology Division (106)
  4. Thoracic Oncology (106)
  5. GSK Faculty (86)
  6. Department of Pathology and Laboratory Medicine (85)

More Groups

People
  1. Marc Ladanyi (59)
  2. Romel Somwar (38)
  3. Mark Kris (30)
  4. Gregory Riely (29)
  5. Maria Arcila (28)
  6. Charles Rudin (27)

More People

Years
  1. 2025 (2)
  2. 2024 (16)
  3. 2023 (10)
  4. 2022 (11)
  5. 2021 (9)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (18)
  2. Clinical Cancer Research (13)
  3. Journal of Thoracic Oncology (13)
  4. JCO Precision Oncology (8)
  5. Cancer Research (7)
  6. Cancer Discovery (6)

More Publications

Publishers
  1. American Association for Cancer Research (28)
  2. American Society of Clinical Oncology (27)
  3. Elsevier Inc. (18)
  4. Nature Publishing Group (12)
  5. Oxford University Press (7)
  6. Nature Research (2)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel activating MAP2K1 in-frame deletion mediates acquired resistance to ROS1 TKIs in a patient with ROS1 fusion-positive NSCLC
    Meeting Abstract

    Sato, H.; Schoenfeld, A.; Siau, E.; Suzawa, K.; Yue, C.; Offin, M.; Drilon, A.; Davare, M.; Riely, G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study
    Meeting Abstract

    Schram, A. M.; Benayed, R.; Somwar, R.; Rekhtman, N.; Arcila, M. E.; Ladanyi, M.; Hyman, D. M.; Drilon, A. E.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • MET inhibitor resistance in patients with MET exon 14-altered lung cancers
    Meeting Abstract

    Guo, R.; Offin, M.; Brannon, A. R.; Chow, A.; Delasos, L.; Somwar, R.; Wilkins, O.; Scott, K.; Tian, Y.; Cecchi, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A bioinformatics framework for high-sensitivity detection and monitoring of oncogenic gene fusions in plasma cfDNA
    Meeting Abstract

    Patel, J.; Hasan, M.; Meng, F.; Jing, X.; Tam, G.; Johnson, I.; Zheng, Y.; Bandlamudi, C.; Stewart, C.; Won, H.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save